Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry
To assess the value of biologically enriched Normal Tissue Complication Probability (NTCP) models integrating clinical, dosimetric, and biological markers, specifically the RadioDtect© assay based on phosphorylated ATM (Ataxia-Telangiectasia Mutated, pATM) quantification.
We considered 67 patients with head-and-neck cancer receiving curative-intent radiotherapy. We developed logistic NTCP models for severe acute/late toxicities (grade ⩾3) using (i) the pATM-based RadioDtect test, (ii) clinical-dosimetric variables, and (iii) a combined model.

